Latest Conference Articles

July 28th 2018, 6:37pm

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

July 28th 2018, 5:44am

International Lung Cancer Congress

Vassiliki A. Papadimitrakopoulou, MD, shares insight on how the lung cancer paradigm continues to evolve with the identification of targetable driver mutations, the challenges that remain, and the ongoing clinical trial efforts designed to better reach patients and improve their outcomes.

July 28th 2018, 4:05am

International Lung Cancer Congress

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

July 28th 2018, 2:28am

International Lung Cancer Congress

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

July 27th 2018, 11:25pm

International Lung Cancer Congress

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

July 27th 2018, 10:25pm

International Lung Cancer Congress

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.

July 27th 2018, 4:51am

International Lung Cancer Congress

Molecular pathologists have helped to advance translational research significantly for lung cancer over the past 10 years; nowhere is that more obvious than in EGFR-mutant non-small cell lung cancer.

July 27th 2018, 4:20am

International Lung Cancer Congress

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

July 27th 2018, 4:06am

International Lung Cancer Congress

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

July 27th 2018, 3:14am

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.

July 27th 2018, 3:13am

International Lung Cancer Congress

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

July 20th 2018, 11:31pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).

July 20th 2018, 11:30pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

July 20th 2018, 11:21pm

Pan Pacific Lymphoma Conference

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

July 20th 2018, 11:18pm

Pan Pacific Lymphoma Conference

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

July 20th 2018, 11:08pm

Pan Pacific Lymphoma Conference

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

July 20th 2018, 9:50pm

Pan Pacific Lymphoma Conference

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

July 20th 2018, 7:55pm

Pan Pacific Lymphoma Conference

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

July 20th 2018, 7:53pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

July 20th 2018, 7:44pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.